Most of the time, psoriasis is the first symptom of psoriatic arthritis. It causes silvery-white skin lesions called plaques, which may appear on your scalp, elbows, knees, and lower back. Eventually, ...

The study grouped 32,098 patients with psoriasis or psoriatic arthritis (PsA) into their respective categories based on biologic treatment, which included TNFi (n = 20,314), IL-17i (n = 5,073), IL ...

We’ll discuss the distinct traits of psoriatic arthritis in Black patients, and the various environmental and genetic factors ...

The FDA has accepted Alvotech (ALVO) and Teva's (TEVA) applications for AVT05, their proposed biosimilar to J&J's ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...

Switching among biologic therapies is common practice in patients with rheumatoid arthritis who have an inadequate ... patients without dose escalation. Drug Patients (n) Total cost of care ...

A West Virginia University legal scholar says current laws may be giving manufacturers of biologic drugs, like antibodies and flu vaccines, too much in the way of legal protections before copycat ...

Healthcare professionals and patients share perspectives on US healthcare hurdles, highlighting the need to improve ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo ...

An ustekinumab biosimilar to Stelara launched in France, completing its rollout across 5 major European markets and paving ...

A RECENT large-scale study published in a dermatology journal provides important insights into the cardiovascular safety of biologic therapies for patients with psoriasis or psoriatic arthritis (PsA).